| Previous Close | 83.87 |
| Open | 84.04 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 84.01 - 85.00 |
| 52 Week Range | 24.55 - 92.97 |
| Volume | 2,284,835 |
| Avg. Volume | 1,730,284 |
| Market Cap | 102.41B |
| Beta | 0.73 |
| PE Ratio (TTM) | 11.74 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.40%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Zacks•2 days ago
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
- Zacks•3 days ago
Is Sanofi (SNY) a Great Stock for Value Investors?
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
- MarketWatch•4 days ago
UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment
Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam shares ...
